This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Methoxyphenamine
- DrugBank Accession Number
- DB13624
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Methoxyphenamine (DB13624)
- Weight
- Average: 179.2588
Monoisotopic: 179.131014171 - Chemical Formula
- C11H17NO
- Synonyms
- 2-Methoxymethamphetamine
- Méthoxyphénamine
- Methoxyphenamine
- Methoxyphenaminum
- Metoxifenamina
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Asthma Combination Product in combination with: Chlorpheniramine (DB01114), Aminophylline (DB01223), Noscapine (DB06174) •••••••••••• ••••••• Used in combination for symptomatic treatment of Asthma Combination Product in combination with: Noscapine (DB06174), Aminophylline (DB01223), Chlorpheniramine (DB01114) •••••••••••• ••••••• Used in combination to treat Coughing Combination Product in combination with: Aminophylline (DB01223), Noscapine (DB06174), Chlorpheniramine (DB01114) •••••••••••• ••••••• Used in combination to treat Rhinorrhoea Combination Product in combination with: Noscapine (DB06174), Chlorpheniramine (DB01114), Aminophylline (DB01223) •••••••••••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UBeta-2 adrenergic receptor regulatorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Methoxyphenamine. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Methoxyphenamine. Acemetacin The risk or severity of hypertension can be increased when Methoxyphenamine is combined with Acemetacin. Acetazolamide Acetazolamide may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level. Acetophenazine Acetophenazine may decrease the stimulatory activities of Methoxyphenamine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Methoxyphenamine hydrochloride 52V8BVV7FX 5588-10-3 FGSJNNQVSUVTPW-UHFFFAOYSA-N
Categories
- ATC Codes
- R03CB02 — Methoxyphenamine
- Drug Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Adrenergics for Systemic Use
- Agents producing tachycardia
- Agents that produce hypertension
- Amines
- Amphetamines
- Drugs for Obstructive Airway Diseases
- Ethylamines
- Neurotransmitter Agents
- Non-selective Beta-adrenergic Agonists
- Phenethylamines
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Sympathomimetics
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenethylamines
- Direct Parent
- Amphetamines and derivatives
- Alternative Parents
- Phenylpropanes / Phenoxy compounds / Methoxybenzenes / Anisoles / Aralkylamines / Alkyl aryl ethers / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Amine / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Ether / Hydrocarbon derivative / Methoxybenzene / Organic nitrogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J3Z5SRI26Z
- CAS number
- 93-30-1
- InChI Key
- OEHAYUOVELTAPG-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3
- IUPAC Name
- [1-(2-methoxyphenyl)propan-2-yl](methyl)amine
- SMILES
- CNC(C)CC1=CC=CC=C1OC
References
- General References
- FDA Thailand Product Information: Asmeton-S (methoxyphenamine/noscapine/aminophylline/chlorpheniramine) oral tablets [Link]
- External Links
- Human Metabolome Database
- HMDB0041930
- ChemSpider
- 3974
- 29704
- ChEBI
- 134817
- ChEMBL
- CHEMBL2010507
- Wikipedia
- Methoxyphenamine
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.783 mg/mL ALOGPS logP 2.13 ALOGPS logP 2.08 Chemaxon logS -2.4 ALOGPS pKa (Strongest Basic) 10.04 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 21.26 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 54.94 m3·mol-1 Chemaxon Polarizability 20.79 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0a4i-9200000000-d79e651be7bca6f4ff90 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0abd-1900000000-f725238d8bad4d028fe7 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0900000000-3dfde102eadb75d15921 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-9600000000-fe0ef996dba3b2d0faa3 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-9600000000-122dcdc8294dcbc28df0 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-053u-4900000000-e245bd7db6aad1451118 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-9600000000-f55768d31addd22994ee Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 146.2191364 predictedDarkChem Lite v0.1.0 [M-H]- 135.50241 predictedDeepCCS 1.0 (2019) [M+H]+ 146.7497364 predictedDarkChem Lite v0.1.0 [M+H]+ 139.20726 predictedDeepCCS 1.0 (2019) [M+Na]+ 146.3565364 predictedDarkChem Lite v0.1.0 [M+Na]+ 148.69649 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Regulator
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
- Gene Name
- ADRB2
- Uniprot ID
- P07550
- Uniprot Name
- Beta-2 adrenergic receptor
- Molecular Weight
- 46458.32 Da
References
- Li Q, Wang J, Zheng YY, Yang L, Zhang Y, Bian L, Zheng J, Li Z, Zhao X, Zhang Y: Comparison of zonal elution and nonlinear chromatography in determination of the interaction between seven drugs and immobilised beta(2)-adrenoceptor. J Chromatogr A. 2015 Jul 3;1401:75-83. doi: 10.1016/j.chroma.2015.05.012. Epub 2015 May 14. [Article]
Drug created at June 23, 2017 20:45 / Updated at February 21, 2021 18:54